Beacon Pharma posts record Tk194cr profit in FY26 to spend Tk250cr on oncology plant
The move aims to expand its manufacturing footprint, boost future revenues and strengthen research capabilities to meet international regulatory standards, according to the company's price-sensitive statement.
Beacon Pharmaceuticals PLC has announced a massive investment plan of Tk250 crore to set up its second oncology production facility.
The decision was approved during the company's board meeting yesterday (15 October).
The move aims to expand its manufacturing footprint, boost future revenues and strengthen research capabilities to meet international regulatory standards, according to the company's price-sensitive statement.
Keep updated, follow The Business Standard's Google news channel
According to a price-sensitive disclosure issued by the drugmaker, the new facility will significantly enhance its annual production capacity.
Upon completion of oncology production facility 2, the company's annual output will increase by 37.97 crore tablets, 21.10 crore capsules, 2.53 crore blisters and 2 crore vials of injectables.
Beacon Pharmaceuticals expects this new facility to have a substantial positive impact on its long-term revenue growth.
Alongside the investment announcement, the company released its audited financial statements for the fiscal year ended 30 June 2026, displaying a robust financial performance driven by a 31% year-on-year increase in sales.
Beacon Pharmaceuticals saw its earnings per share (EPS) more than double, rising 105% to Tk8.41 for FY2025–26, up from Tk4.10 recorded in the previous fiscal year.
Reflecting this stellar financial growth, the company recommended an 11% cash dividend for the year ended 30 June 2026.
The record date for the dividend distribution has been scheduled for 10 November. Shareholders will vote on the proposed dividend and financial statements during the company's annual general meeting (AGM), set to take place via a digital platform on 13 December.
